INTRODUCTION

Coronary heart disease (CHD) arising from atherosclerosis is the leading cause of death and morbidity worldwide [1]. The pathophysiology of CHD is complex and not yet fully understood. The oxidative hypothesis is a classical theory on atherosclerosis that oxidative stress is a critical and final common mechanism [2]. Growing evidence indicates that inflammation also influences all stages of atherosclerosis [3]. Apoptosis is a form of programmed cell death that occurs in multicellular organisms and is involved in various biologic processes including development, aging, and chemical-induced cell death. Inappropriate apo-
tosis is associated with many human diseases such as neurodegenerative diseases, ischemic damage, autoimmune disorders, and cancers [4].

Vascular smooth muscle cells (VSMCs) are strongly implicated across all stages of CHD. Migration of VSMCs from the media into the subendothelial region and aberrant proliferation are characteristic findings in atheroma formation. Apoptosis is frequently associated with increased proliferation, which largely accounts for high rates of VSMC turnover [5]. Furthermore, VSMCs are predominant in the fibrous atheroma cap and lesional apoptosis of VSMC triggers plaque progression and its vulnerability to rupture [6]. In addition, the number of VSMCs in the media layer decreases through apoptosis in association with arterial aging [7,8].

Oxidatively modified low-density lipoprotein (LDL) contributes significantly to atherosclerosis by adversely affecting not only the monocytes, macrophages, and vascular endothelial cells (VECs), but also VSMCs [9]. We previously reported that lysophosphatidylcholine (lysoPC), an active component of oxidized LDL, exerts a cytotoxic effect mainly via apoptosis in VSMCs [10].

There is convincing evidence regarding a causal relationship between estrogen deficiency and CHD in women. Women with early menopause have an increased risk of CHD [11]. In addition, estrogen therapy, if initiated early after menopause, reduces CHD risk [12]. Estrogen has various action mechanisms underlying its cardioprotective effects. In addition to the beneficial systemic effects on lipid profiles, blood pressure, and glucose metabolism, the direct action of estrogen on arteries may be important [13].

To explore the mechanism underlying direct vascular actions of estrogen in CHD, the effects of 17β-estradiol (E₂) on lysoPC-induced apoptosis in cultured VSMCs were investigated in the present study.

MATERIALS AND METHODS

Materials

Sprague–Dawley rats were purchased from Charles River Japan (Hino, Japan). Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F-12 medium (DMEM/F-12) without phenol red, fetal bovine serum (FBS), trypsin-ethylenediaminetetraacetic acid (EDTA), and penicillin-streptomycin were obtained from GIBCO BRL (Grand Island, NY, USA). 2,7’-dichlorofluorescein diacetate (DCF-DA) was purchased from (Calbiochem, Darmstadt, Germany). LysoPC, 17β-E₂, ICI 182,780, and all other chemicals were from Sigma Chemical Co. (St. Louis, MO, USA). Monoclonal antibody for α-smooth muscle actin was obtained from DAKO (Glostrup, Denmark), anti-β-actin antibody was from Sigma Chemical Co., and antibodies against Bax, Bcl-2, precursors of caspase-9 and -8, active form of caspase-3, and cytochrome c oxidase subunit IV were bought from Cell Signaling Technology, Inc. (Beverly, MA, USA). DCF-DA and ICI 182,780 were dissolved in dimethyl sulfoxide (DMSO) and 17β-E₂ in ethanol (EtOH). All the other chemicals were resolved in distilled water.

Cell culture

The thoracic aortas from 3-month-old Sprague–Dawley rats (160–180 g) were got rid of and the VSMCs were isolated with an enzymatic digestion method as previously described [14]. The VSMCs were cultured in DMEM/F-12 (50 : 50) containing 10% FBS without phenol red and antibiotics. The cells were positively stained for α-smooth muscle actin. Cells in a nearly confluent state were made quiescent by incubation for at least 48 hours in a defined serum-free medium including insulin (0.5 μM), transferrin (5 mg/mL), and ascorbate (0.2 mM).

This study protocol was evaluated and approved by the Institutional Animal Care and Use Committee of Samsung Biomedical Research Institute (approval no. C-A3-220-2), which has been accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International and abides by the guide of the Institute of Laboratory Animal Resources.

Propidium iodide staining

Adherent and detached cells were harvested, pooled, washed once in phosphate-buffered saline (PBS), and fixed in ice-cold 70% (vol/vol) EtOH in distilled water. After centrifugation, the cells were washed and resuspended in cold PBS containing RNase (5 mg/mL) and incubated at 37°C for 30 minutes. Finally, propidium iodide (PI, 1 mg/mL) was added and the cells incubated in the dark for 10 minutes and then analyzed for cell cycle distribution using flow cytometry and Cell Quest software (Becton-Dickinson, San Jose, CA, USA).

Western blot analysis

Cells were lysed in lysis buffer (50 mM Tris-HCl [pH, 7.5], 200 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, and 0.1% sodium dodecyl sulfate [SDS]) containing 1 mM phenylmethylsulfonyl fluoride on ice for 30 minutes. Proteins were separated employing SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). The membranes were incubated with primary antibodies at room temperature for 1 hour. Blots were developed with peroxidase-conjugated secondary antibody and proteins visualized with enhanced chemiluminescence methods (Amersham Biosciences, Piscataway, NJ, USA) following the manufacturer’s recommendations. β-actin was utilized as a control.

Preparation of subcellular fractions

The cells were collected by centrifugation and washed twice with PBS. The cells were resuspended in homogenization buffer (250 mM sucrose, 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 10 mM Tris-HCl, pH 7.4) containing a proteinase inhibitor cocktail (Roche, Indianapolis, IN, USA), incubated 10 minutes on ice, homogenized, and centrifuged at 700 ×g for 10 minutes. The supernatant was centrifuged again at 10,000 ×g for 30 minutes. The resulting supernatant contained the cytosolic fraction and the pellet the mitochondrial fraction.

Analysis of intracellular formation of reactive oxygen species

Production of intracellular reactive oxygen species (ROS) was determined using DCF-DA, a cell-permeable oxidation-sensitive probe. Cells were incubated in 10 μM DCF-DA at 37°C for 30 minutes and harvested by trypsinization and washed three times with cold PBS solution. The median fluorescence intensity was measured using flow cytometry and CellQuest software (Becton-Dickinson).

In vitro transient transfection and reporter assay

To examine the nuclear factor (NF)-κB activation, the VSMCs were transfected with a reporter plasmid containing the luciferase reporter gene linked to five repeats of the NF-κB binding sites, as previously described [15]. Briefly, the VSMCs (1 × 10⁵ cells/well) were cultured to approximately 70% confluence in 24-well plates. Cells were then transiently co-transfected with 1 μg of NF-κB-luciferase reporter plasmid and 1 μg of β-galactosidase plasmid using Lipofectamine plus (Invitrogen, Carlsbad, CA, USA). At 6 hours after transfection, cells were starved for 48 hours, and then exposed to 15 μM lysoPC for the indicated time periods. Luciferase activity was measured with a luciferase assay kit (Promega, Madison, WI, USA) with signal detection for 5 seconds in a luminometer (Promega Inc., Fremont, CA, USA). A β-galactosidase enzyme assay (Promega) was applied to determine the β-galactosidase activity at 420 nm with a SmartSpec 3000 spectrophotometer (Bio-Rad). The results are expressed relative to the NF-κB activity compared with controls after normalizing for β-galactosidase activity and protein concentration.

Data analysis and statistics

Data are expressed as means ± standard error of the mean. The Kruskal–Wallis test and Wilcoxon rank sum test were applied for statistical analysis using IBM Statistics Package for Social Sciences ver. 25.0 (IBM Corp., Armonk, NY, USA). A two-tailed P value < 0.05 was considered statistically significant.

RESULTS

17β-estradiol inhibited lyso phosphatidylcholine-induced apoptosis in cultured vascular smooth muscle cells

We previously reported that lysoPC induced VSMC apoptosis in a dose-dependent manner at a concentration of 15 μM or higher [10]. Co-treatment of 17β-E₂ did not influence lysoPC-induced apoptotic cell death assessed using PI staining (data not shown). In the present study, the effects of 17β-E₂ after 24 hours of pre-treatment were investigated. Time-course study showed that 10⁻⁶ M of 17β-E₂ significantly decreased lysoPC-induced (15 μM) apoptosis after 12 hours (Fig. 1A). In a dose-response experiment at 18 hours of treatment (Fig. 1B), lysoPC significantly increased apoptosis and EtOH (0.1%), a vehicle, did not affect apoptosis. Compared with vehicle-treated controls, 17β-E₂ reduced apoptotic cell death in a dose-dependent manner and significant reductions were observed at 10⁻⁷ M or higher concentration (Fig. 1B).

In addition, the effects of 17β-E₂ on the apoptosis pathway were investigated. As previously reported [10], Western blot analysis (Fig. 2A) showed that 15 μM of lysoPC decreased caspase-9 and -8 precursors and increased the active form of caspase-3; EtOH (0.1%) had no influence on caspase expression. After 24 hours of pre-treatment, 17β-E₂ (10⁻⁶ M) reversed the changes
in all three caspases compared with vehicle-treated controls (Fig. 2A). We previously showed that although protein levels of Bax and Bcl2 were unchanged, lysoPC treatment increased Bax translocation from the cytosol to mitochondria [10]. In the present study, Bax and Bcl2 expression under lysoPC treatment was not altered with \(17\beta\)-E2 based on Western blot analysis (data not shown). However, lysoPC-induced Bax translocation was not changed with EtOH (0.1%). Pretreatment with \(17\beta\)-E2 (10\(^{-6}\) M) for 24 hours significantly decreased mitochondrial Bax and simultaneously increased cytosolic Bax compared with vehicle-treated controls (Fig. 2B). The results indicate \(17\beta\)-E2 inhibits apoptotic cell death in VSMCs treated with lysoPC by down-regulating both extrinsic and intrinsic apoptosis pathways.

Mechanisms of \(17\beta\)-estradiol action

Mechanisms underlying estrogen actions were further investigated. In our previous study [10], lysoPC induced VSMC apoptosis via an oxidant mechanism. Changes in intracellular ROS production in VSMCs are shown in Figure 3A. LysoPC (15 µM) increased ROS 1 hour after treatment and EtOH (0.1%) did not affect ROS production. Compared with vehicle-treated controls, \(17\beta\)-E2 (10\(^{-6}\) M) significantly decreased ROS production after 24 hours of pre-treatment. LysoPC-induced apoptosis was also reported to be NF-κB-dependent [10]. The NF-κB activity was increased in response to 15 µM lysoPC treatment for 1 hour and did not change with EtOH (0.1%), as shown in Figure 3B. Pre-treatment with \(17\beta\)-E2 (10\(^{-6}\) M) for 24 hours significantly suppressed NF-κB activity compared with vehicle-treated controls. In addition, we previously reported that estrogen receptor (ER) was expressed in rat VSMCs [16]. PI staining showed that DMSO (0.1%), a vehicle, did not affect VSMC apoptosis, and ICI 182,780 (10\(^{-6}\) M), a specific ER antagonist, significantly blocked estrogen effects (Fig. 3C). The results indicate \(17\beta\)-E2 reduces apoptosis via receptor-mediated mechanism and antioxidant activity including NF-κB inhibition.

**DISCUSSION**

In the present study, direct effects of estrogen on apoptotic cell death of lysoPC-induced VSMCs were investigated. \(17\beta\)-E2 significantly suppressed apoptosis via an antioxidant activity and receptor-mediated mechanism.

VSMC apoptosis is induced by various stimuli and stressors including pro-inflammatory cytokines, oxidized LDL, high levels of nitric oxide, and mechanical injury [17]. We previously showed that cytotoxic effects of lysoPC are mediated by apoptosis and not by necrosis [10]. VSMCs treated with oxidized LDL undergo apoptosis via both death receptor (extrinsic) and mitochondrial (intrinsic) pathways [17]. Consistently, ly-
**Fig. 2.** Effects of 17β-estradiol (E₂) on apoptosis pathway in cultured vascular smooth muscle cells stimulated with lysophosphatidylcholine (LysoPC, 15 µM) after 24-hour pre-treatment. 17β-E₂ effects on (A) caspases and (B) Bax translocation based on Western blot analysis. Representative blots are shown in the upper section of each panel. The intensity of the bands was densitometrically determined and normalized to corresponding β-actin or COX IV bands as appropriate. Graphic data are depicted in the lower part of the panel. Data are expressed as means ± standard error of the mean. DSF: defined serum-free, EtOH: ethanol, COX IV: cytochrome c oxidase subunit IV. *P < 0.05.
soPC activated caspase-3 and -8, markers of a common and death receptor pathway, respectively, and increased Bax translocation from the cytosol to mitochondria [10]. An increase in mitochondrial Bax would enhance release of cytochrome c from mitochondria and then activation of caspase-9, a marker of the mitochondrial pathway. These observations support an involvement of dual pathways in lysoPC-induced apoptosis.

In the present study, 17\( \beta \)-E2 significantly suppressed apoptotic cell death of VSMCs treated with lysoPC in a dose-dependent manner based on PI staining. The effects of estrogen occurred at an approximate physiologic concentration of 10\(^{-7}\) M. 17\( \beta \)-E2 inhibited caspase-3 activation. Furthermore, estrogen treatment attenuated activation of caspase-8 and -9 and decreased Bax translocation to the mitochondria. To the best of our knowledge, this is the first study in which 17\( \beta \)-E2 down-regulated lysoPC-induced VSMC apoptosis by inhibiting both apoptosis pathways.

In the present study, the mechanism of estrogen action against apoptosis was investigated. 17\( \beta \)-E2 rapidly mitigated ROS production at 1 hour of lysoPC treatment. Furthermore, 17\( \beta \)-E2 suppressed NF-\( \kappa \)B activity, a major redox-sensitive signaling pathway [18]. The results support the antioxidant effects of estrogen. In addition, estrogen effects against apoptosis were significantly, but not fully, blocked by ICI 182,780, indicating partial contribution of an ER-mediated mechanism.

Chronic apoptosis of VSMCs accelerates atherosclerosis [19]. Furthermore, plaque rupture in early lesions is frequently subclinical because VSMCs repair the rupture and reorganize the associated thrombus. Subsequently, this may lead to an obstructive lesion later [1]. In advanced plaques, VSMC apoptosis contributes to plaque thrombogeneity and incites plaque microcalcification [17]. Furthermore, insufficient clearance of apoptotic VSMCs causes plaque inflammation [20]. These actions account, at least in part, for plaque insta-
bility, rupture, and ensuing acute coronary syndrome. Inhibition of apoptotic cell death of VSMCs due to 17β-E2 could be a key mechanism for direct estrogen actions on arteries.

Post hoc analysis of Women's Health Initiative data revealed a significant time trend in CHD risk with menopausal hormone therapy (MHT) and the risk was significantly increased by 28% in women 20 years and longer since menopause [12]. Even though the underlying mechanism is not fully known, arterial status with aging would be attributed considerably to the contrasting effects by timing of MHT. In younger menopausal women with early atherosclerosis, MHT is beneficial. The present study reporting an anti-apoptotic effect of estrogen on VSMCs would provide additional mechanism for MHT benefit. In contrast, beginning MHT in late postmenopausal women with established atherosclerosis might be harmful by decreased number of functional ER and vasodilation, and increased inflammatory activation and plaque instability [13].

Oxidative stress also causes apoptosis of VECs and cardiomyocytes [21]. Estrogen prevented VEC apoptosis induced with hydrogen peroxide [22] and attenuated cardiomyocyte apoptosis induced with hypoxia [23]. Anti-apoptotic actions of estrogen via these mechanisms further contribute to the prevention of CHD.

VSMC apoptosis is a notable feature in arterial aging [7] and increased oxidative stress in VSMCs is a causative factor of aortic stiffening [24]. Estrogen could have a favorable impact on arterial aging by suppressing VSMC apoptosis via an antioxidant activity as shown in the present study. Estrogen therapy in postmenopausal women might improve pulse-wave velocity, a common measurement of arterial stiffness [25].

Although using VSMCs derived from rat aortas is an established in vitro model for CHD, cells from human coronary arteries might be more appropriate for further experiments. In addition, caspase-independent pathways of apoptosis, including apoptosis-inducing factor and endoplasmic reticulum stress, have been reported [21]. Additional studies are needed to further elucidate the mechanism of estrogen action on VSMC apoptosis.

In conclusion, 17β-E2 inhibits lysoPC-stimulated apoptotic cell death in cultured VSMCs mediated by an antioxidant activity and receptor-mediated mechanism. This action of estrogen would contribute to the prevention of CHD with MHT in early menopausal women.

ACKNOWLEDGMENTS

This work was supported in part by the Sungkyunkwan University Foundation for Corporate Collaboration (S-2011-0683-000), the Samsung Biomedical Research Institute grant (C-A0-021-3), the Samsung Medical Center Research Fund (PHX1000071), and the IN-SUNG Foundation for Medical Research (C-A5-802-1).

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res 2016; 118: 692-702.
2. Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative stress in atherosclerosis. Curr Atheroscler Rep 2017; 19: 42.
3. Pant S, Deshmukh A, Gurumurthy GS, Pothineni NV, Watts TE, Romeo F, et al. Inflammation and atherosclerosis—revisited. J Cardiovasc Pharmacol Ther 2014; 19: 170-8.
4. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495-516.
5. McCarthy NJ, Bennett MR. The regulation of vascular smooth muscle cell apoptosis. Cardiovasc Res 2000; 45: 747-55.
6. Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res 2014; 114: 214-26.
7. Sawabe M. Vascular aging: from molecular mechanism to clinical significance. Geriatr Gerontol Int 2010; 10 Suppl 1: S213-20.
8. Lee SJ, Park SH. Arterial ageing. Korean Circ J 2013; 43: 73-9.
9. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, et al. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci 2001; 947: 199-205; discussion 205-6.
10. Lee DY, Kang YH, Choi DS, Lee YJ, Rhuy MR, Yoon BK. Cytotoxic Effects of lysophosphatidylcholine on vascular smooth muscle cells. J Korean Soc Menopause 2012; 18: 139-46.
11. Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 2016; 1: 767-76.
12. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA
13. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308: 1583-7.
14. Owens GK, Loeb A, Gordon D, Thompson MM. Expression of smooth muscle-specific alpha-isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J Cell Biol 1986; 102: 343-52.
15. Yoon BK, Kang YH, Oh WJ, Park K, Lee DY, Choi D, et al. Impact of lysophosphatidylcholine on the plasminogen activator system in cultured vascular smooth muscle cells. J Korean Med Sci 2012; 27: 803-10.
16. Yoon BK, Oh WJ, Kessel B, Roh CR, Choi D, Lee JH, et al. 17Beta-estradiol inhibits proliferation of cultured vascular smooth muscle cells induced by lysophosphatidylcholine via a nongenomic antioxidant mechanism. Menopause 2001; 8: 58-64.
17. Grootaert MOJ, Moulis M, Roth L, Martinet W, Vindis C, Bennett MR, et al. Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis. Cardiovasc Res 2018; 114: 622-34.
18. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 2005; 7: 395-403.
19. Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, et al. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res 2008; 102: 1529-38.
20. Clarke MC, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res 2010; 106: 363-72.
21. Kim NH, Kang PM. Apoptosis in cardiovascular diseases: mechanism and clinical implications. Korean Circ J 2010; 40: 299-305.
22. Sudoh N, Toba K, Akishita M, Ako J, Hashimoto M, Iijima K, et al. Estrogen prevents oxidative stress-induced endothelial cell apoptosis in rats. Circulation 2001; 103: 724-9.
23. Hsieh DJ, Kuo WW, Lai YP, Shibu MA, Shen CY, Pai P, et al. 17β-estradiol and/or estrogen receptor β attenuate the autophagic and apoptotic effects induced by prolonged hypoxia through HIF-1α-mediated BNIP3 and IGFBP-3 signaling blockage. Cell Physiol Biochem 2015; 36: 274-84.
24. Canugovi C, Stevenson MD, Vendrov AE, Hayami T, Robidoux J, Xiao H, et al. Increased mitochondrial NADPH oxidase 4 (NOX4) expression in aging is a causative factor in aortic stiffening. Redox Biol 2019; 26: 101288.
25. da Costa LS, de Oliveira MA, Rubim VS, Wajngarten M, Aldrighi JM, Rosano GM, et al. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol 2004; 94: 1453-6.